



Investor Information

Exentis' licensee Laxxon Medical enters into a cooperation with Hovione for the industrial manufacturing of 3D printed tablets

- ◆ **Conclusion of a long-term strategic cooperation agreement between Laxxon Medical and Hovione, a leading manufacturer in the pharmaceutical industry**
- ◆ **Accelerated establishment of the Exentis clean room 3D technology platform within the pharmaceutical industry**
- ◆ **Large-scale production of innovative 3D printed tablets with a freely adjustable release profile for the active pharmaceutical ingredients**

Stetten, Switzerland, 24 March 2023 – Exentis Group AG provides the only 3D technology platform worldwide that enables industrial large-scale production of both industrial and clean room applications.

The strategic cooperation currently agreed between Laxxon Medical and Hovione combines Laxxon Medical's expertise in pharmaceutical applications with Hovione's product and process development, engineering and manufacturing expertise.

Under the terms of the agreement, Hovione will initially establish the Exentis 3D technology platform for industrial clean room production at its manufacturing facilities in Portugal and subsequently at its manufacturing facilities in New Jersey, USA. The latest generation of Exentis clean room 3D production systems to be used are modularly extendable and can be scaled up to capacities of millions of tablets per day.



Modular Exentis pharma clean room 3D production system for the manufacturing of millions of tablets

Compared to conventional tablets, the innovative tablets which are mass-produced using Exentis 3D technology have a freely adjustable release profile for the active pharmaceutical ingredients within the human body.

Dr. Gereon Heinemann, CEO of Exentis Group AG: “Together with Laxxon Medical, our long-standing 3D community member, we were able to convince Hovione of the performance of our Exentis 3D technology platform. The strategic cooperation will further accelerate the broad deployment of our clean room 3D technology and production systems within the pharmaceutical industry.”

About Exentis

As a solution provider, Exentis has the only proprietary 3D technology platform worldwide that allows industrial large-scale production. Industrialized Additive Manufacturing is universally applicable. For industrial or cleanroom applications. With free choice of materials, such as metals, ceramics, polymers, pharmaceutical or bio-printing products. Highly flexible 3D production technology combines rework-free component geometries with advantageous cost-benefit ratios. The cold printing process

in use is sustainable and conserves materials as well as resources. Our customers, the Exentis 3D community members, can choose between exclusive in-house manufacturing under license agreements or having Exentis produce millions of applications for them as a contract manufacturer.

About Laxxon Medical

Laxxon Medical is dedicated to developing patented 3D pharmaceutical solutions that optimize products and benefit patients. The foundation of Laxxon Medical's pharmaceutical solutions is its state-of-the-art 3D screen printing technology and the intellectual property that surrounds it. The commitment to innovation and health is driven by the expertise, integrity, agility and diversity of the Laxxon Medical team. Laxxon Medical offers three disruptive pathways for strategic opportunities in the pharmaceutical industry: advanced patented generics, patent extension through technology transfer, and new drug development.

About Hovione

Hovione is an international corporation with more than 60 years of experience in pharmaceutical development and manufacturing operations. As a Contract Development and Manufacturing Organization (CDMO), Hovione has a fully integrated offering of services for drug substance, drug product intermediate and drug product. The company has four FDA inspected sites in the USA, Portugal, Ireland and China as well as development laboratories in the USA and Portugal. Hovione provides pharmaceutical customers services for the development and compliant manufacturing of innovative drugs as well as customized product solutions across the entire drug life cycle.

For further information please contact:

Benjamin del Fabro
Head of Investor Relations

+41 44 520 46 00
b.delfabro@exentis-group.com

Visit us also on our website at www.exentis-group.com.